Feedback Share Discussion Threads

[yump] 09/6/2021 14:26

Ydderf

We can all Google and find those (some of us did) but they’re not all the same and they’re not the same as Bleepa.

“Imaging systems” has hundreds of results.

The market is differentiated and has segments, just like any market.

For starters, Bleepa feeds off Pacs, so a pacs system is not a competitor at all.

Not really sure what you’re doing here.

You could just ask questions if you’re interested.

[davwal] 09/6/2021 13:16

There are several good, up and coming health services in Eastern Europe too.

[ydderf] 09/6/2021 13:15

Here's a serious question. How are hospitals managing to treat patients, and radiographic departments disseminate essential images, to medics at present? I know an appreciable number or medics and medical institutions through other involvements and whenever I have asked this question, the answer shows they have it covered. It is one of the most basic functions of a radiographic department, the prompt communication of detailed images to the oncologist to a local screen. Could it be that nobody here has conducted any desk-top research and therefore are not aware of the real medical world?

There are too many competing systems to list but here are links to typical offerings:







As always, please don't 1) shoot the messenger 2) try to bully me off this board with ad hominem attacks. The silent majority here would probably welcome a balanced discussion

[ged5] 09/6/2021 12:46

There was this from yesterday's tweet from BleepaMe. Remember WISH?

Got a small mention here and a mention in the table of shortlisted innovations.

"Telemedicine can also take the format of a messaging app between doctors to facilitate discussions and shared experiences and recommendations when it comes to more challenging medical cases. Such is the case of “Bleepa,”; one of the WISH 2020 shortlisted innovators mentioned in Table 1. Here the challenge is avoiding the leak of confidential and sensitive information, such as the patient's condition and medical history."

I realise Yump and possibly others want FDBK to focus on the NHS but I don't mind them trying on three fronts. NHS, India and Qatar. Give me a big contract from any of them.

[lr2] 09/6/2021 11:28

Thanks Duc. That's one webpage I won't need to look at again.

[ducatiman] 09/6/2021 11:25

Copied from here LR2?

[lr2] 09/6/2021 10:49

Not heard of 'Trade and Focus' before.

[ducatiman] 08/6/2021 19:41

Just read the update. More Jam tomorrow!
£120k invoiced, obviously not Bleepa!
£2.2m left, that won’t keep the lights on for long with the salary burden!
Crunch time approaches.

[yump] 08/6/2021 11:47

I’m glad I didn’t have a job where I had to decide between the usual patients and covid.

Re Bleepa: perhaps the reality is that its been impossible to get meetings about Bleepa or any other new tech, so giving a few talks at conferences is all thats left.

Although that assumes the managers are all ultra busy like the clinicians - which could be debateable.

Just don’t dress it up please TO and leave the world domination until later !

[lr2] 08/6/2021 11:42

"The Company has already invoiced £0.12million of revenue to be recognised during the current financial year in accordance with the Company's accounting policies and the Directors expect revenues to grow as sales of Bleepa increase during the rest of the financial year."

As the current financial year only started 8 days ago, that £120k revenue is surprising. If only they could persuade us shareholders it was repeatable.

365 days / 8 days = 45.625 x £120k = £5.475 mil.

I'd be happy if they could just cover expenditure for now.

Bet Trevor's got some negativity on this subject.

[ged5] 08/6/2021 09:51

Round about the amount of cash I was expecting.

Contracts are needed and they seem to take time. Enough cash until end of year but will their be enough contracts to see us beyond that?

The wording in the RNS seemed positive to me but its actions that are needed.

Bad Gateway, Chopper Harris, the NHS is working well where I live. Decided to do something about my knee which needs replacing. Got phone appointment with GP, video appointment with Physio. Further appointment in a couple of weeks.

Unfortunately it led to two other medical problems. Physical appointment with GP, blood tests, referral to consultant. Appointment at hospital within the week. Outpatients was busy. Further consultation in a few weeks.

So yes the NHS is working fine. Covid cases are up but hospitalisations and deaths are down. The NHS seems to be getting back to business as usual.

[davwal] 08/6/2021 09:09

"Bleepa leads at the forefront of the market". Oh yeah..? I'd not want to be following at the tail end of the market then. An update of more padding than substance and a good dollop of the usual jam tomorrow. They really can't seriously seek more funding without genuine progress and solid client interest. But apparently that's all just around the next corner...

[chopper harris1] 08/6/2021 07:47

bad gateway,

Good point. I’m struggling at the moment to make any sort of appointment with my GP for a consultation about a medical condition which is beginning to concern me.

My local GP surgery is still obsessed with Covid-19, to the detriment of patients with other, potentially serious conditions.

[dave4545] 08/6/2021 07:37

freddy

I was referring to another stock I hold not FDBK

[bad gateway] 08/6/2021 07:36

Have we still got an NHS for them to sell to?
Sold last year as it was obvious the clapping was stupid as everything was shut and their patients abandoned. Genuine question - Has the NHS reopened for anything but covid yet?

[pugugly] 08/6/2021 07:30

ydderF - Agreed - Nothing (imo) to suggest that the immediate and significant growth in sales that we need to avoid another funding round - If correct at what level will the company be able to raise funds?

[ydderf] 08/6/2021 07:21

dave4545 "unaudited net cash as at 31 May 2021 was £2.2 million" not the £3+ million you assert. Looks like the spending on Bleepa development will continue for a while yet, which suggests a further fund raising may be necessary in the absence of revenue? Market cap looks a but toppy in the circumstances but I doubt if anyone pays attention to fundamentals here.

In reality the original Feedback with good revenue and prospects from TexRad has morphed into a cash-burning software startup with a market cap of £10m . Try not to shoot the messenger please, focus on the Company not ad hominem attacks on me - it might help maybe a majority of (silent) shareholders here who are really not represented while you bully and chase away reasonable criticism

[dave4545] 08/6/2021 07:14

Cannot really get excited about that update, like most stocks FDBK got spiked higher in the boom last year after Covid.

I mean I have a 11 mil stock with net £3 mil+ of cash and £20-40 mil of turnover and it's friendless. Guess it's all in the future of course for Fdbk

Cannot see any fireworks today on that update.

[sonie01] 06/6/2021 20:44

Well said yump

[lr2] 06/6/2021 16:17

I can only assume it will be positive as the session is delivered in partnership with Bleepa. I couldn't find a previous connection either.

[ducatiman] 06/6/2021 15:32

Thanks LR2. I have looked on the Orcha website and searched Bleepa. Not found. I wonder what the connection is?

[lr2] 05/6/2021 21:25

Taking stock of messaging apps: using safe, secure and compliant clinical messaging to drive efficiencies, negate clinical risk and improve care delivery

17 Jun 2021 08:00 - 08:55 S - Specialist sessions 3

The European Commission’s Medical Device Directive states that any platform that ‘displays digital patient images for the purpose of diagnosis’ by clinicians should hold a CE mark as a regulated medical device. However, with the current prevalence of clinicians using mainstream messaging and clinical communication platforms without it, there is a considerable liability risk for both organisations and individual clinicians.

Healthcare organisations also have an obligation under GDPR as data controllers, which means that communication apps that contain patient information should include a data processing agreement between the manufacturer and any organisation whose employees are using it. This applies to apps offered to clinicians under a ‘freemium’ model, even if the organisation itself has not encouraged the use of the tool and, in many cases, its clinicians may be using it outside of the organisation's knowledge.

This panel discussion seeks to explore the broader benefits of using a safe, secure and compliant clinical communications platform, including integrating with other clinical systems; recording discussions as part of the patient record; and improving efficiencies and working practices for busy clinicians at a time when the elective care backlog is particularly challenging.

This session is delivered in partnership with Bleepa.

Speakers

Tim Andrews, Chief Operating Officer - ORCHA

James Devine, Director of Acute Care - NHS Confederation

Darryn Hale, Senior Associate - DAC Beachcroft

Dr Tom Oakley, CEO - Bleepa